Home | Welcome to Contract Pharma   
Last Updated Monday, September 22 2014
Print

Otsuka Acquires Rights to Eisai’s Dacogen



Published March 31, 2014
Related Searches: Development
Eisai, Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., has sold the rights to DACOGEN (decitabine) for Injection to Otsuka Pharmaceutical Co., Ltd. DACOGEN is approved for treatment of patients with myelodysplastic syndromes
 
Through an exclusive worldwide license, Otsuka gains full development and commercialization rights for the product in the former Eisai territories of the U.S., Canada and Japan. Eisai will retain its rights for DACOGEN in Mexico. Otsuka will also gain the patent for Eisai’s metabolic enzyme inhibitor E7727.
 
Eisai's marketing rights for DACOGEN originate from a worldwide license from Astex Pharmaceuticals, Inc., which was acquired by Otsuka in October 2013.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On